Transthyretin Amyloidosis (ATTR)
Heart Failure Society of America (HFSA) 2024
Congress Details
September 27-30, 2024
Atlanta, GA, USA
The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.
For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Congress Materials
Presentation Type
Location
Presenter
Related Materials
Transthyretin Amyloidosis (ATTR)
American College of Cardiology (ACC) 2026
Transthyretin Amyloidosis (ATTR)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025
Transthyretin Amyloidosis (ATTR)
American Heart Association (AHA) 2025
Transthyretin Amyloidosis (ATTR)
Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial
European Journal of Heart Failure
Transthyretin Amyloidosis (ATTR)
Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis
Journal of Clinical Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicenter Study
Annals of Medicine
